Goetz MP, Bagegni NA, Batist G, Brufsky A, et al. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol 2023;34:1141-1151.
PMID: 38072514